Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy

Journal of Nuclear Medicine

Volumn 39, Issue 7, 1998, Pages 1230-1236

  Gates, Vanessa L ^b   Carey, James E ^b   Siegel, Jeffry A ^b   Kaminski, Mark S ^b   Wahl, Richard L ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NONE

Author keywords

Iodine 131 therapy; Nuclear Regulatory Commission; Patient release; Radioimmunotherapy

Indexed keywords

CD20 ANTIGEN; IODINE 131; MONOCLONAL ANTIBODY;

ARTICLE; B CELL LYMPHOMA; DRUG HALF LIFE; HODGKIN DISEASE; HUMAN; OUTPATIENT CARE; PRIORITY JOURNAL; RADIATION DEPTH DOSE; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOISOTOPE THERAPY;

ADULT; AMBULATORY CARE; ANTIBODIES, MONOCLONAL; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; RADIATION DOSAGE; RADIATION PROTECTION; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0031867028     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-465.
2. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131 -anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974-1981.
3. United States Nuclear Regulatory Commission. Medical use of byproduct material standards for protection against radiation, 10 CFR Part 35. Washington DC: USNRC; 1991.
4. United States Nuclear Regulatory Commission. Release of patients administered radioactive materials, Regulatory Guide 8.39. Washington, DC: USNRC; 1997.
5. Schneider S, McGuire SA. Regulatory analysis on criteria for the release of patients administered radioactive material, NUREG-1492. Washington, DC: USNRC; 1996.
6. Jacobson AP, Plato PA, Toeroek D. Contamination of the home environment by patients treated with iodine-131: initial results. Am J Public Health 1978;68:225-230.
7. 131I. Health Phys 1980;38:467-481.
8. Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978;80:849-857.
9. Wahl RL, Wissing J, del Rosario R, Zasadny KR. Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. J Nucl Med 1990;31:84-89.
10. Zasadny KR, Wahl RL. A simplified method for determining therapeutic activity to administer for radioimmunotherapy [Abstract]. J Nucl Med 1996;37:43P.
11. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992;10:1696-1711.
12. Gates VL, Zasadny KR, Fisher SJ, Spaulding S, Kaminski MS, Wahl RL. How well do whole body tracer kinetics predict whole body therapy kinetics in I-131 anti-B1 lymphoma radioimmunotherapy? [Abstract] J Nucl Med 1997;38:251P
13. Hall ET. The hidden dimension. New York: Doubleday Co., Inc.; 1966:117-121.
14. National Council on Radiation Protection and Measurements. Dose limits for individuals who receive exposure from radionuclide therapy patients, NCRP Commentary No. 11. Bethesda, MD: NCRP; 1995.
15. Carey JE, Kumpuris TM, Wrobel MC. Release of patients containing therapeutic dosages of iodine-131 from hospitals. J Nucl Med Technol 1995;23:144-149.
16. National Council on Radiation Protection and Measurements. Precautions in the management of patients who have received therapeutic amounts of radionuclides, NCRP Report No. 37. Bethesda, MD: NCRP; 1970.
17. Culver CM, Dworkin HJ. Radiation safety considerations for post-iodine-131 thyroid cancer therapy. J Nucl Med 1992;33:1402-1405.
18. Culver CM, Dworkin HJ. Radiation safety considerations for post-iodine-131 hyperthyroid therapy. J Nucl Med 1991;32:169-173.
19. 131I therapy: time for change? Lancet 1992;340:912-913.
20. Barrington SF, Kettle AG, Thomson WH, et al. RCP guidelines on radiation protection following radioiodine therapy for thyrotoxicosis: are they appropriate? [Abstract]. Nucl Med Commun 1996;17:275.
21. Thomson WH, Harding LK. Radiation protection issues associated with nuclear medicine out-patients. Nucl Med Commun 1995;16:879-892.
22. 131I therapy outpatients [Abstract]. Nucl Med Commun 1996;17:275.
23. Thomas SR, Stabin MG, Chen CT, Samaratunga RC. MIRD pamhlet no. 14: a dynamic urinary bladder model for radiation dose calculations. J Nucl Med 1992;33:783-802.